Rebecca Cook
Faculty Member
Last active: 4/15/2019

  1. Targeting BRCA1 localization to augment breast tumor sensitivity to poly(ADP-Ribose) polymerase inhibition. Yang ES, Nowsheen S, Rahman MA, Cook RS, Xia F (2012) Cancer Res 72(21): 5547-55
    › Primary publication · 22962264 (PubMed) · PMC3771348 (PubMed Central)
  2. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Balko JM, Cook RS, Vaught DB, Kuba MG, Miller TW, Bhola NE, Sanders ME, Granja-Ingram NM, Smith JJ, Meszoely IM, Salter J, Dowsett M, Stemke-Hale K, González-Angulo AM, Mills GB, Pinto JA, Gómez HL, Arteaga CL (2012) Nat Med 18(7): 1052-9
    › Primary publication · 22683778 (PubMed) · PMC3693569 (PubMed Central)
  3. Optical imaging of metabolism in HER2 overexpressing breast cancer cells. Walsh A, Cook RS, Rexer B, Arteaga CL, Skala MC (2012) Biomed Opt Express 3(1): 75-85
    › Primary publication · 22254170 (PubMed) · PMC3255344 (PubMed Central)
  4. MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Turke AB, Song Y, Costa C, Cook R, Arteaga CL, Asara JM, Engelman JA (2012) Cancer Res 72(13): 3228-37
    › Primary publication · 22552284 (PubMed) · PMC3515079 (PubMed Central)
  5. Local breast cancer spatial patterning: a tool for community health resource allocation to address local disparities in breast cancer mortality. Brantley-Sieders DM, Fan KH, Deming-Halverson SL, Shyr Y, Cook RS (2012) PLoS One 7(9): e45238
    › Primary publication · 23028869 (PubMed) · PMC3460936 (PubMed Central)
  6. HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation. Vaught DB, Stanford JC, Young C, Hicks DJ, Wheeler F, Rinehart C, Sánchez V, Koland J, Muller WJ, Arteaga CL, Cook RS (2012) Cancer Res 72(10): 2672-82
    › Primary publication · 22461506 (PubMed) · PMC3693553 (PubMed Central)
  7. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sánchez V, Chakrabarty A, Dave B, Cook RS, Pao W, McKinely E, Manning HC, Chang J, Arteaga CL (2011) Proc Natl Acad Sci U S A 108(12): 5021-6
    › Primary publication · 21385943 (PubMed) · PMC3064360 (PubMed Central)
  8. ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis. Cook RS, Garrett JT, Sánchez V, Stanford JC, Young C, Chakrabarty A, Rinehart C, Zhang Y, Wu Y, Greenberger L, Horak ID, Arteaga CL (2011) Cancer Res 71(11): 3941-51
    › Primary publication · 21482676 (PubMed) · PMC3204389 (PubMed Central)
  9. Cooperative signaling between Slit2 and Ephrin-A1 regulates a balance between angiogenesis and angiostasis. Dunaway CM, Hwang Y, Lindsley CW, Cook RS, Wu JY, Boothby M, Chen J, Brantley-Sieders DM (2011) Mol Cell Biol 31(3): 404-16
    › Primary publication · 21135133 (PubMed) · PMC3028625 (PubMed Central)
  10. H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3. Chakrabarty A, Rexer BN, Wang SE, Cook RS, Engelman JA, Arteaga CL (2010) Oncogene 29(37): 5193-203
    › Primary publication · 20581867 (PubMed) · PMC2945381 (PubMed Central)